What the FDA labels say about taking them together
Cyclosporine and metoclopramide
Cyclosporine's FDA label of August 10, 2026 names metoclopramide in its drug interactions section, and metoclopramide's label names cyclosporine too. The metoclopramide label: “Drugs with Absorption Altered due to Increased Gastrointestinal Motility Clinical Impact The effect of metoclopramide on other drugs is variable. …”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the metoclopramide FDA label on DailyMed (effective May 18, 2026, ANI Pharmaceuticals, Inc.).
What does the cyclosporine label say about metoclopramide?
Cyclosporine label, drug interactionsDrugs That Increase Cyclosporine Concentrations Calcium Channel Blockers Antifungals Antibiotics Glucocorticoids Other Drugs diltiazem fluconazole azithromycin methylprednisolone Allopurinol nicardipine itraconazole clarithromycin Amiodarone verapamil ketoconazole erythromycin Bromocriptine voriconazole quinupristin/ dalfopristin colchicine danazol imatinib metoclopramide nefazodone oral contraceptives HIV Protease Inhibitors The HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, and saquinavir) are known to inhibit cytochrome P-450 3A and thus could potentially increase the concentrations of cyclosporine, however no formal studies of the interaction are available.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the metoclopramide label say about cyclosporine?
Metoclopramide label, drug interactions… therapeutic effect of the interacting drug. For digoxin monitor therapeutic drug concentrations and increase the digoxin dose as needed (see prescribing information for digoxin). Drugs with Increased Absorption (e.g., sirolimus, tacrolimus, cyclosporine): Monitor therapeutic drug concentrations and adjust the dose as needed. See prescribing information for the interacting drug.
Gimoti label (Evoke Pharma, Inc., February 20, 2026), drug interactionsIntervention; Drugs with Decreased Absorption (e.g., digoxin, atovaquone, posaconazole oral suspension Interaction does not apply to posaconazole delayed-release tablet., fosfomycin): Monitor for reduced therapeutic effect of the interacting drug. For digoxin, monitor therapeutic drug concentrations and increase the digoxin dose as needed (see prescribing information for digoxin). Drugs with Increased Absorption (e.g., sirolimus, tacrolimus, cyclosporine): Monitor therapeutic drug concentrations and adjust the dose as needed. See prescribing information for the interacting drug.
Source: FDA drug label (Gimoti, NDA209388), Evoke Pharma, Inc., effective February 20, 2026 (SPL set 95269b1f-779c-4ca0-9f86-e74e677f9900), via openFDA
Source: FDA drug label (Metoclopramide), NDA017854 (Ani Pharms), as published by ANI Pharmaceuticals, Inc., effective May 18, 2026 (SPL set 797aad80-0597-42f8-99d5-39de180c3b5a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Metoclopramide | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Acid reflux and ulcers, Nausea and vomiting |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.0439 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once